December 20, 2018
--
As reported by Proactive Investors Canada, Lexaria Bioscience Corp. announced that it has been granted two new US patents. Lexaria is a drug delivery platform innovator.
The patents, US Patent 10,103,225 and US Patent 10,084,044, are both titled “Food and beverage compositions infused with lipophilic active agents and methods of use thereof”, and relate to cannabinoid-infused beverage compositions. The beverage compositions use Lexaria’s proprietary DehydraTECH process. According to Lexaria, this technology is designed to, among other things, enhance the performance of beneficial compounds in ingestible products across four categories: taste, smell, speed of action, bioabsorption and bioavailability.
Lexaria now holds ten patents in total – six in the US and four in Australia. As reported by Market Watch, all of these patents are within Lexaria’s first patent family.
The newly granted patents provide protection on compositions and methods for making such compositions. Each composition uses both non-psychoactive (e.g., CBD) and psychoactive cannabinoids (e.g., THC).
The company is pursuing two additional related patents in Australia and hopes they are granted by the end of 2018. Lexaria has 50 patent applications filed worldwide.
Author: Alexandra Murray
Comments